KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsBuildingsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLand & ImprovementsLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Teva Pharmaceutical Industries (TEVA) Other Non-Current Assets (2016 - 2025)

Historic Other Non-Current Assets for Teva Pharmaceutical Industries (TEVA) over the last 17 years, with Q4 2025 value amounting to -$1.3 billion.

  • Teva Pharmaceutical Industries' Other Non-Current Assets fell 38787.88% to -$1.3 billion in Q4 2025 from the same period last year, while for Dec 2025 it was -$1.3 billion, marking a year-over-year decrease of 38787.88%. This contributed to the annual value of -$1.3 billion for FY2025, which is 38787.88% down from last year.
  • Teva Pharmaceutical Industries' Other Non-Current Assets amounted to -$1.3 billion in Q4 2025, which was down 38787.88% from $1.8 billion recorded in Q3 2025.
  • Teva Pharmaceutical Industries' 5-year Other Non-Current Assets high stood at $1.8 billion for Q2 2025, and its period low was -$1.5 billion during Q4 2023.
  • Moreover, its 5-year median value for Other Non-Current Assets was $466.0 million (2024), whereas its average is $484.8 million.
  • Per our database at Business Quant, Teva Pharmaceutical Industries' Other Non-Current Assets plummeted by 44580.5% in 2023 and then skyrocketed by 32442.4% in 2025.
  • Quarter analysis of 5 years shows Teva Pharmaceutical Industries' Other Non-Current Assets stood at $515.0 million in 2021, then decreased by 14.37% to $441.0 million in 2022, then tumbled by 445.8% to -$1.5 billion in 2023, then skyrocketed by 130.3% to $462.0 million in 2024, then tumbled by 387.88% to -$1.3 billion in 2025.
  • Its Other Non-Current Assets was -$1.3 billion in Q4 2025, compared to $1.8 billion in Q3 2025 and $1.8 billion in Q2 2025.